FindTrial
Sign In

A RANDOMIZED STUDY, POSPECTIVE, ON THREE DIFFERENT STRATEGY OF HIV POSITIVE NAIVE FOR THE ANTIRETROVIRAL THERAPY

A RANDOMIZED STUDY, POSPECTIVE, ON THREE DIFFERENT STRATEGY OF HIV POSITIVE NAIVE FOR THE ANTIRETROVIRAL THERAPY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001164-32-IT
Enrollment
Unknown
Registered
2007-08-07
Start date
2005-04-05
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV INFECTION CHRONIC AND NAIVE. VIREMIE &gt

Interventions

Trade Name: VIDEX*30CPS GASTR 400MG Pharmaceutical Form: Gastro-resistant capsule, hard INN or Proposed INN: Didanosine CAS Number: 69655-05-6 Concentration unit: mg milligram(s) Concentration type: e

Sponsors

AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: Verificare l¡¦efficacia di una terapia antiretrovirale di associazione con lamivudina (3TC) + didanosina (DDI) + efavirenz (EFV) in mono somministrazione giornaliera in confronto a lamivudina (3TC) + didanosina (DDI) + atazanavir/ritonavir (ATZ/rtv) in monosomministrazione giornaliera e a zidovudina (AZT) + tenofovir (TDF) + efavirenz (EFV). La scelta dei pazienti per quanto riguarda l¡¦inizio della terapia antiretrovirale sarà conforme alle indicazioni delle linee guida nazionali ed internazionali. ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026